Animal Blood Plasma and Derivatives Market Size, Share, Growth, and Industry Analysis, By Type (Immunoglobulin, Fibrinogen, Serum albumin, Fetal bovine serum, Thrombin, New born calf serum), By Application (Food and Beverages, Pharmaceuticals, Cosmetics, Feed), Regional Insights and Forecast to 2032

• 

   Request a Free Sample To Get More Information on this Market

ANIMAL BLOOD PLASMA AND DERIVATIVESMARKET REPORT OVERVIEW

global animal blood plasma and derivatives market size was USD 1.14 billion in 2023 and market is projected to touch USD 1.88 billion by 2032 at CAGR 5.71% during the forecast year.

The animal blood plasma and derivatives market is a crucial sector within the global biopharmaceutical industry. It encompasses the collection, processing, and distribution of blood plasma and its derived products from various animal sources, including bovine and porcine. These products play a vital role in pharmaceuticals, veterinary medicine, and research applications.

The market has witnessed steady growth due to increasing demand for plasma-derived therapies, rising prevalence of chronic diseases, and advancements in bioprocessing techniques. Additionally, the growing awareness about the therapeutic benefits of animal-derived plasma products has further propelled market expansion.

COVID-19 IMPACT

"Market Growth Restrained by Pandemic due to Supply Chain Disruptions"

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic has had a notable impact on the animal blood plasma and derivatives market. On one hand, the increased focus on healthcare and bio therapeutics during the pandemic has led to a surge in demand for blood plasma and its derivatives for various medical applications, including the development of therapies and vaccines. On the other hand, disruptions in the supply chain and logistical challenges have presented hurdles for the collection and processing of animal blood products. Additionally, the economic impact of the pandemic may have influenced the purchasing behavior of consumers and healthcare providers, potentially affecting market dynamics. Overall, while there has been an increased demand for certain blood plasma products, the market has also faced challenges related to production and distribution during the pandemic.

LATEST TRENDS

"Emerging Therapeutic Applications and Technological Advancements Leads Growth In The Market"

One of the latest trends in the animal blood plasma and derivatives market is the emergence of novel therapeutic applications and technological advancements. Innovations in plasma fractionation techniques, such as the development of advanced filtration and purification processes, are leading to the production of higher quality and more specific plasma-derived products. Moreover, there is a growing focus on utilizing animal blood plasma derivatives in niche therapeutic areas, including regenerative medicine, immunotherapy, and personalized medicine. These trends are reshaping the market landscape, offering new opportunities for market players to meet evolving healthcare needs and improve patient outcomes. Additionally, ongoing research in areas like nanotechnology and bioprocessing is expected to further enhance the efficacy and safety of plasma-derived products, driving continued growth and innovation in this dynamic market.

ANIMAL BLOOD PLASMA AND DERIVATIVES MARKET SEGMENTATION

By Type

Based on type the market can be categorized into Immunoglobulin, Fibrinogen, Serum albumin, Fetal bovine serum, Thrombin, New born calf serum.

Immunoglobulins derived from animal blood plasma play a crucial role in the pharmaceutical industry.

Animal blood plasma-derived fibrinogen is a vital component in haemostatic therapies, aiding in blood clotting. Market demand is driven by surgical and trauma care applications.

Animal blood plasma-derived serum albumin is a vital protein used in pharmaceuticals, diagnostics, and research, driving growth in the market.

Fetal bovine serum, a rich source of nutrients for cell culture, is a critical component in biopharmaceutical and research applications, driving market demand.

Animal blood plasma-derived thrombin, a crucial clotting enzyme, finds applications in surgery and wound care, bolstering the market's growth.

Newborn calf serum, sourced from bovine calves, is a valuable component in cell culture media, supporting growth in the biotechnology sector.

By Application

Based on application, the market can be divide into Food and Beverages, Pharmaceuticals, Cosmetics, Feed and Others.

DRIVING FACTORS

"Biotechnology Advancements to Propel the Market Growth"

Advancements in biotechnology have significantly propelled and expanded the animal blood plasma and derivatives market share. Cutting-edge techniques in cell culture and bioprocessing have increased the demand for serum albumin, immunoglobulins, and other derivatives sourced from animal blood plasma. These components are crucial in cell culture media, vaccines, and therapeutic products. Furthermore, improvements in purification and processing technologies have enhanced the quality and yield of these products, driving their adoption across various industries.

"Rising Demand in Healthcare to Drive the Market Growth"

The healthcare sector has been a major driver of the animal blood plasma and derivatives market. Immunoglobulins, derived from animal blood plasma, are essential in treating a range of immune-related disorders, including primary immunodeficiency diseases. The COVID-19 pandemic has further underscored the importance of these products in developing vaccines and therapies. Additionally, serum albumin, with its critical role in maintaining colloidal osmotic pressure in the blood, finds extensive application in critical care settings. As the global population continues to age and face various health challenges, the demand for these essential blood plasma products is anticipated to remain robust.

RESTRAINING FACTOR

"Regulatory Challenges to Poses a Significant Restrain on the Market Growth"

Navigating complex regulatory frameworks poses a significant restraining factor for the animal blood plasma and derivatives market. Strict guidelines govern the collection, processing, and distribution of these products to ensure safety and quality. Adhering to these standards demands substantial investments in compliance measures, which can be a barrier for smaller players. Additionally, variations in regulatory requirements across different regions and countries can lead to logistical complexities, hindering market access and growth.

• 

   Request a Free Sample To Get Analysis on Major Geographic Market

ANIMAL BLOOD PLASMA AND DERIVATIVES MARKET REGIONAL INSIGHTS

"North America to Dominate the Market owing to Advanced Research Infrastructure"

North America is poised to dominate the animal blood plasma and derivatives market growth. With a well-established biopharmaceutical sector, advanced research infrastructure, and stringent regulatory standards, the region is at the forefront of innovation and production in this field. Additionally, a high prevalence of chronic diseases and a strong focus on healthcare advancements contribute to the robust demand for products derived from animal blood plasma. The presence of key market players and extensive R&D activities further solidify North America's position as the leading market for animal blood plasma and derivatives.

KEY INDUSTRY PLAYERS

"Key Industry Players Shaping the Market through Innovation and Market Expansion"

Several key industry players are driving innovation and market expansion in the animal blood plasma and derivatives sector. Companies like Grifols, CSL Limited, Takeda Pharmaceuticals, and Kedrion Biopharma are at the forefront of research and development, continuously introducing novel products and technologies. They invest heavily in advanced processing techniques, ensuring high-quality derivatives. Additionally, strategic collaborations, mergers, and acquisitions enable these companies to expand their market reach and offer a comprehensive portfolio of products to meet diverse industry needs.

List of Top Animal Blood Plasma And Derivatives Companies

• ANZCO Foods Ltd. (New Zealand)
• Lake Immunogenics, Inc. (U.S.)
• Kraeber and Co GmbH (Germany)
• Auckland BioSciences Ltd. (New Zealand)
• Bovogen Biologicals Pty Ltd. (Australia)
• Rocky Mountain Biologicals Inc. (U.S.)
• Proliant Inc. (U.S.)
• Merck KGaA (Germany)
• LAMPIRE Biological Laboratories, Inc. (U.S.)
• Thermo Fisher Scientific, Inc. (U.S.)

INDUSTRIAL DEVELOPMENT

2022: The industrial development of the animal blood plasma and derivatives market has seen significant progress in recent years. Advances in bioprocessing technologies and purification methods have improved the efficiency and quality of production. This has led to increased yields of high-quality products, meeting the growing demand in various industries. Moreover, the market has witnessed a surge in research and development activities, leading to the introduction of innovative products and applications. These include specialized cell culture media, advanced vaccines, and cutting-edge therapies, further expanding the market's scope.

REPORT COVERAGE

The animal blood plasma and derivatives market is a dynamic and essential sector within the biopharmaceutical industry. It encompasses the collection, processing, and distribution of vital plasma-derived products for a range of therapeutic and research applications. The market has seen steady growth, driven by increasing demand for plasma-derived therapies and advancements in bioprocessing techniques. Key regions like North America and Europe have traditionally dominated, but emerging economies in Asia-Pacific are showing substantial growth potential. Additionally, the industry has demonstrated resilience in the face of challenges, such as the COVID-19 pandemic, highlighting its critical role in global healthcare.